Summit Therapeutics Inc. (SMMT) Form 8-K — Jul 23, 2026

$SMMTForm 8-KItems 1.01, 9.01Filed Jul 23, 2026, 4:34 PM ET0001193125-26-314214Original filing

Summit Therapeutics Inc. entered into a distribution agreement with J.P. Morgan Securities LLC to sell up to $380 million of its common stock through an 'at-the-market' offering program. The company is not obligated to sell any shares and can suspend the offering at any time.

Key figures

Gross Proceeds: 380,000,000
Sales Agent Commission: 3.0%

Price after filing

1 day: +0.8%7 days: -8.1%30 days: -10.0%

Close on the filing date to close N calendar days later (from $14.63). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.